Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
40/100
Both the amygdala and the hippocampus are involved in the pathogenesis of a number of neurologic conditions, including temporal lobe epilepsy, postanoxic amnesia, and Alzheimer's disease.
-
Down syndrome (DS) is a major cause of congenital heart and gut disease and mental retardation.
Why it matters
This molecular mapping study of two patients with partial duplications of chromosome 21 defined regions that may contain genes for congenital heart disease, duodenal stenosis and some facial and skeletal features, and noted that people with Down syndrome can have an Alzheimer-like dementia. It is genetic mapping work and reports no treatment, cure or prevention for Alzheimer's disease.
-
Chromosome 21-specific yeast artificial chromosomes (YACs) have been constructed by a method that performs all steps in agarose, allowing size selection by pulsed-field gel electrophoresis and the use of nanogram to microgram quantities of DNA.
Why it matters
This work built tools to map chromosome 21, the chromosome linked to Alzheimer disease and Down syndrome. It does not test any treatment, cure, or prevention; it is an early laboratory step toward studying these disorders.
-
In patients with end-stage renal disease, nervous system dysfunction remains a major cause of disability.
-
The human amyloid beta protein is the major constituent of the brain amyloid plaques found in Alzheimer disease.
Why it matters
This study mapped the mouse version of the human amyloid beta protein gene to mouse chromosome 16, in a region that shares genes with the Down syndrome region of human chromosome 21. It is a basic genetics finding and does not test or propose any treatment, cure or prevention for Alzheimer's disease.
-
Immunocytochemical staining patterns for glial fibrillary acidic protein (GFAP) and S-100 protein (S100P) were compared in cerebral cortex, basal ganglia and white matter of eight cases with hepatic encephalopathy (HE), including four cases of Wilson's disease and four of liver cirrhosis, and of eight age-matched controls, using the peroxidase-antiperoxidase method on adjacent paraffin sections.
Why it matters
In brain tissue from eight hepatic encephalopathy cases and eight controls, most Alzheimer type II glia showed S100P but not GFAP immunoreactivity, and the proportion of GFAP-positive glial cells decreased in the cortex. This concerns hepatic encephalopathy and does not report a treatment, cure or prevention for Alzheimer's disease.
-
A family is described with familial myoclonic epilepsy associated with mitochondrial myopathy.
-
Across diverse viral infections, strong convergence was observed in innate immune activation pathways, including microglial priming and NLRP3 inflammasome signaling, accompanied by chronic production of proinflammatory cytokines (IL-1β, TNF-α, IFN-γ).
Why it matters
This review reports that different viral infections converge on neuroinflammatory pathways that may accelerate Alzheimer's-related processes, especially in genetically susceptible people. It states viral infections alone are unlikely to cause Alzheimer's, so this does not establish a way to treat, cure or prevent the disease.
-
In part 1 of the study, the patients with CSVD showed significant differences in Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT)-study, AVLT-immediate, AVLT-delay, AVLT-recognition, Trail Making Test (TMT)-A, TMT-B, and Verbal Fluency Test -fruits/vegetables compared with HCs.
Why it matters
In this open-label pilot study, 20 patients with cerebral small vessel disease showed improved scores on several cognitive tests after 14 days of high-definition transcranial direct current stimulation targeting the left dorsolateral prefrontal cortex. The authors say further research is needed to refine treatment plans and evaluate the approach, so this is early preliminary evidence.
-
Vascular dementia (VaD) is a leading cause of cognitive decline and arises from heterogeneous cerebrovascular pathologies, most commonly cerebral small vessel disease and chronic cerebral hypoperfusion.
Why it matters
This review describes how microglia have dual, stage-dependent effects in vascular dementia and how molecular pathways and microRNAs might be targeted to shift microglia from pro-inflammatory to reparative states. It is a review of mechanisms and proposed targets, not a tested treatment, cure or prevention.
-
Down syndrome (DS), caused by trisomy 21, is the most prevalent genetic condition associated with accelerated aging and near-universal development of early-onset Alzheimer's disease (AD).
Why it matters
This review proposes that Down syndrome involves a failure of the proteostasis network that contributes to early-onset Alzheimer's disease. It discusses mechanisms from published evidence and does not report a tested treatment, cure or prevention.
-
Down syndrome (DS), caused by trisomy 21, is the most prevalent genetic condition associated with accelerated aging and near-universal development of early-onset Alzheimer’s disease (AD).
Why it matters
This review describes Down syndrome as a disorder of proteostasis network failure that contributes to accelerated aging and early-onset Alzheimer's disease. It discusses mechanisms only and reports no tested treatment, cure, or prevention.
-
TDP-43 proteinopathy is central to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Why it matters
The study found that TDP-43 pathology impairs DNA repair in motor neuron diseases through reduced levels of a metabolite called F2,6BP, and that adding F2,6BP reduced TDP-43 aggregates in patient-derived neurons and improved motor deficits in a fruit fly model. This is early laboratory work that points to a possible therapeutic target, not a proven treatment.
-
39/100
Amyloid precursor protein (APP) is a key player in various neuronal functions but also the source for toxic Aβ that accumulates in the brain of Alzheimer patients.
Why it matters
This study shows that disruption of the HOPS complex impairs retromer-mediated recycling of APP, causing APP accumulation in late endosomes where BACE1 contributes to toxic APP C-terminal fragments, and enhances exosomal secretion of these fragments. The findings establish a mechanistic link between HOPS loss-of-function and aberrant APP processing, but they are laboratory results with implications for neurodegeneration rather than a demonstrated treatment.
-
We found interactions between APOE4 and cognitive states in the aperiodic EEG exponent and the spectral power ratio (SPR).
Why it matters
This study found interactions between APOE ε4 and cognitive states in aperiodic electroencephalogram measures, and a lower spectral power ratio in cognitively normal participants compared to those with non-amnestic mild cognitive impairment. It describes associations and does not test any treatment, cure, or prevention.
-
Autologous hematopoietic stem/progenitor cell (HSC)–gene therapy (GT) represents a promising therapeutic option for progranulin (PGRN)–related neurodegenerative diseases due to mutations in the PGRN encoding gene ( GRN ), such as frontotemporal dementia (FTD) and neuronal ceroid lipofuscinosis 11 (CLN11).
Why it matters
In mice lacking progranulin, transplanting genetically corrected hematopoietic stem cells restored some progranulin and corrected lipid accumulation, gliosis, and social recognition. This is animal research on progranulin-related conditions such as frontotemporal dementia, so it does not yet show a treatment for Alzheimer's disease in people.
-
These findings suggest probable amyloid association with early microglial activation, while tau pathology is closely tied to wider distribution of neuroinflammation.
Why it matters
Using PET imaging, this study found that neuroinflammation increased in people with amyloid but no cognitive impairment and became more widespread as disease severity worsened, tracking with amyloid and tau pathology. It is observational imaging research, so it cannot show whether reducing this inflammation would treat or prevent Alzheimer's disease.
-
Environmental factors like neighborhood disadvantage are also associated with cognitive decline, however, few studies have integrated this with APOE research.
Why it matters
In this study, neither APOE status, neighborhood disadvantage, nor their interaction significantly predicted memory or attention performance. The overall models were not statistically significant, so the study found no evidence that neighborhood disadvantage changes the relationship between APOE and cognition.
-
Peruvian GWAS identified Amerindian ancestry specific exonic AD susceptibility variant p.H157Y. This variant has been previously reported as AD marker in Han Chinese populations with extreme effect size, but its rarity and contradictory findings in other groups suggest a potential ancestry‐specific effect.
Why it matters
This genome-wide association study in the Peruvian population replicated the known APOE4 and TREML2 Alzheimer disease loci and identified a rare TREM2 missense variant, p.H157Y, on an Amerindian ancestral background. Functional studies suggest the variant may enhance TREM2 signaling, but the work is genetic and does not itself test a treatment.
-
There is significant evidence that microglia contribute to neuroinflammation and neurotoxicity in AD 1,2 , yet there is also evidence to the contrary.
Why it matters
This study found that a marker of microglial activity, CSF sTREM2, was associated with Alzheimer's pathology differently at different stages of the disease. In one group with mild cognitive impairment and high amyloid, the microglial response was associated with preserved cognition, suggesting a possible protective role.
-
Understanding the distribution of SV2A in DS will provide insight on changes to synaptic density in populations with accelerated AD neuropathology.
Why it matters
This project is developing methods to measure synaptic density in people with Down syndrome using brain imaging, building on findings in older adults that tau burden is linked to reduced synaptic density. It is early methodological work and does not yet test a treatment or prevention.
-
Understanding the distribution of SV2A in DS will provide insight on changes to synaptic density in populations with accelerated AD neuropathology.
Why it matters
This project is developing brain imaging templates and analysis methods to measure synaptic density in people with Down syndrome, and the work is still in progress. It has not yet produced findings about treating, curing or preventing Alzheimer's disease.
-
39/100
The sample included 61 participants (55.7% female), aged 18-58, with a median education of 12 years (IQR: 10-14).
Why it matters
This study characterized 61 people in Colombia with recently identified PSEN1 variants linked to early-onset inherited Alzheimer's disease, most of whom were still cognitively unimpaired. No significant differences in clinical or cognitive features were found across variants, and the authors note that biomarker and follow-up data are still expected.
-
We sequenced a total of 38,577 nuclei and detected an average of 2,700 genes per cell.
Why it matters
In 3D cultures from PSEN1 G206A carriers, no significant difference was found in PSEN1 or its substrates between early and late age-of-onset groups, but genes involved in presynaptic differentiation, ER stress, neuroinflammation and lipid metabolism differed. This is a cell-culture transcriptomic study exploring why age of onset varies, not a treatment.
-
Higher MIND diet scores during the follow-up were associated with fewer reactive microglia (i.e., less neuroinflammation) in the hippocampus when controlled for age at death, sex, education, calories, and AD pathology (β=-0.035, SE=0.02, p = 0.045), but not with total microglia (β=-4.88, SE=3.08, p = 0.114).
Why it matters
In this community-based neuropathologic study, higher MIND diet scores were linked to fewer reactive microglia in the hippocampus, suggesting less neuroinflammation. The authors state that further studies are needed to see if this lower inflammatory response explains the diet's link to cognitive health in older persons.
From across this topic
10 of the 4,748 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1
- Activated actin-depolymerizing factor/cofilin sequesters phosphorylated microtubule-associated protein during the assembly of alzheimer-like neuritic cytoskeletal striations
- Palmitoylated Prolactin-releasing Peptide Reduced Aβ Plaques and Microgliosis in the Cerebellum: APP/PS1 Mice Study
- Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals
- Alpha-synuclein aggregation induces prominent cellular lipid changes as revealed by Raman spectroscopy and machine learning analysis
- Predicting White Matter Hyperintensity: Leveraging Portable MRI for Accessible Brain Health Screening
- Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies
- Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome
- The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia
- Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies